Q4 2025 13F Holders as of 31 Dec 2025
-
Type / Class
-
Equity / Common Stock ($0.0001 par value) (the "Shares")
-
Shares outstanding
-
74,300,257
-
Total 13F shares
-
76,464,347
-
Share change
-
+26,742,063
-
Total reported value
-
$759,231,269
-
Put/Call ratio
-
99%
-
Price per share
-
$9.93
-
Number of holders
-
145
-
Value change
-
+$269,440,349
-
Number of buys
-
104
-
Number of sells
-
35
Institutional Holders of Lexeo Therapeutics, Inc. - Common Stock ($0.0001 par value) (the "Shares") (LXEO) as of Q4 2025
As of 31 Dec 2025,
Lexeo Therapeutics, Inc. - Common Stock ($0.0001 par value) (the "Shares") (LXEO) was held by
145 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
76,464,347 shares.
The largest 10 holders included
JANUS HENDERSON GROUP PLC, RA CAPITAL MANAGEMENT, L.P., BlackRock, Inc., Paradigm Biocapital Advisors LP, Vestal Point Capital, LP, Frazier Life Sciences Management, L.P., VANGUARD GROUP INC, CITADEL ADVISORS LLC, Avoro Capital Advisors LLC, and Affinity Asset Advisors, LLC.
This page lists
145
institutional shareholders reporting positions in this security
for the Q4 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.